July 28 (Reuters) - GSK forecast a smaller drop in
2021 profit on Wednesday, as the drugmaker topped analysts'
expectations for second-quarter profit after a pick-up in
hospital visits following easing of COVID-19 restrictions
boosted its vaccines division.
"We expect this positive momentum to continue through the
second half of the year driving us towards the better end of our
earnings guidance range for 2021, and meaningful performance
improvement in 2022," Chief Executive Emma Walmsley said.
(Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout
in London
Editing by Mark Potter)